Clinical Trials

Any
    Option:
    Any
    Accrual Status
    Limit to SWOG Trials
    Filter Your Search
    Open
    Phase
    0% Accrual
    Accrual
    0%
    MM1OA-S03
    SWOG Clinical Trial Number
    Open
    Phase
    0% Accrual
    Accrual
    0%
    S2414
    SWOG Clinical Trial Number

    INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)

    Status Notes
    Initial Activation-Effective March 14, 2025, at 12:00 p.m. Pacific Time
    Research Committee(s)
    Lung Cancer
    Symptom Control and Quality of Life
    Activated
    03-14-2025
    ClinicalTrials.gov Registry Number
    06498635
    Open
    Phase
    0% Accrual
    Accrual
    0%
    S2408
    SWOG Clinical Trial Number

    A Randomized Phase III Blinded Trial of lanreotide for the Prevention of Postoperative Pancreatic Fistula

    Research Committee(s)
    Palliative and End of Life Care Committee
    Gastrointestinal Cancer
    Activated
    02-14-2025
    Open
    Phase
    2% Accrual
    Accrual
    2%
    S1900J
    SWOG Clinical Trial Number

    A Phase II Study of Amivantamab SC (subcutaneous) in Participants Previously Treated with High MET-Amplification for Stage IV or Recurrent Non-Small-Cell Lung Cancer (Lung-MAP Sub-Study)

    Status Notes
    S1900J will open to accrual September 27, 2024, effective 3:00 p.m. EST.
    Research Committee(s)
    LungMAP
    Activated
    09-27-2024
    ClinicalTrials.gov Registry Number
    NCT06116682
    Open
    Phase
    4% Accrual
    Accrual
    4%
    S2312
    SWOG Clinical Trial Number

    A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature

    Status Notes
    S2312 active as of 9/3/2024.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    09-03-2024
    ClinicalTrials.gov Registry Number
    06470243
    Open
    Phase
    12% Accrual
    Accrual
    12%
    S2308
    SWOG Clinical Trial Number

    Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

    Status Notes
    S2308 will open to accrual 08/01/2024, effective 3:00 p.m. EST
    Research Committee(s)
    Lymphoma
    Activated
    08-01-2024
    ClinicalTrials.gov Registry Number
    06337318